Cancer Immunoediting: From Immune Surveillance to Immune Escape

Cancer Immunotherapy

Volumn , Issue , 2007, Pages 9-27

  Kim, Ryungsa ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 51349149448     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012372551-6/50066-3     Document Type: Chapter

References (57)

1. Asselin-Paturel C., Trinchieri G. Production of type I interferons: Plasmacytoid dendritic cells and beyond. J. Exp. Med. 2005, 202:461-465.
2. Birkeland S.A., Storm H.H., Lamm L.U., Barlow L., Blohme I., Forsberg B., Eklund B., Fjeldborg O., Friedberg M., Frodin L., et al. Cancer risk after renal transplantation in the Nordic countries 1964-1986. Int. J. Cancer 1995, 60:183-189.
3. Burnet F.M. Cancer: A biological approach. Br. Med. J. 1957, 1:841-847.
4. Burnet F.M. Immunological surveillance in neoplasia. Transplant Rev. 1971, 7:3-25.
5. Cankovic M., Linden M.D., Zarbo R.J. Use of microsatellite analysis in detection of tumor lineage as a cause of death in a liver transplant patient. Arch. Pathol. Lab. Med. 2006, 130:529-532.
6. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994, 1:447-456.
7. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
8. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
9. Dunn G.P., Bruce A.T., Sheehan K.C., Shankaran V., Uppaluri R., Bui J.D., Diamond M.S., Koebel C.M., Arthur C., White J.M., et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 2005, 6:722-729.
10. Ehrlich P. Ueber den jetzigen stand der karzinomforschung. Ned. Tijdschr. Geneeskd. 1909, 5:273-290.
11. Engel A.M., Svane I.M., Mouritsen S., Rygaard J., Clausen J., Werdelin O. Methylcholan-threne-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS 1996, 104:629-639.
12. Engel A.M., Svane I.M., Rygaard J., Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand. J. Immunol. 1997, 45:463-470.
13. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., Hobby P., Sutton B., Tigelaar R.E., Hayday A.C. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001, 294:605-609.
14. Gresser I., Bandu M.T., Brouty-Boye D. Interferon and cell division. IX. Interferon-resistant L1210 cells: Characteristics and origin. J. Natl. Cancer Inst. 1974, 52:553-559.
15. Gresser L., Maury C., Vignaux F., Haller O., Belardelli F., Tovey M.G. Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice. J. Exp. Med. 1988, 168:1271-1291.
16. Haanen J.B., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., von Blomberg B.M., Bloemena E., Scheper R.J., van Ham S.M., et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advance-stage mela- noma patients. Cancer Immunol. Immunother. 2006, 55:451-458.
17. Hayakawa Y., Rovero S., Forni G., Smyth M.J. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. USA 2003, 100:9464-9469.
18. Herberman R.B., Holden H.T. Natural cell-mediated immunity. Adv. Cancer Res. 1978, 27:305-377.
19. Ikehara S., Pahwa R.N., Fernandes G., Hansen C.T., Good R.A. Functional T cells in athymic nude mice. Proc. Natl. Acad. Sci. USA 1984, 81:886-888.
20. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Che X., Iwashige H., Aridome K., Hokita S., Aikou T. Progoostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000, 88:577-583.
21. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 1998, 95:7556-7561.
22. Kim R., Emi M., Tanabe K., Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006, 66:5527-5536.
23. Klein G. Immune surveillance-A powerful mechanism with a limited range. Natl. Cancer Inst. Monogr. 1976, 44:109-113.
24. Kondo E., Koda K., Takiguchi N., Oda K., Seike K., Ishizuka M., Miyazaki M. Proeperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig. Surg. 2003, 20:445-451.
25. Lockhart D.C., Chan A.K., Mak S., Joo H.G., Daust H.A., Carritte A., Douville C.C., Goedegebuure P.S., Eberlein T.J. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001, 129:749-756.
26. MacKie R.M., Reid R., Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 2003, 348:567-568.
27. Maleckar J.R., Sherman L.A. The composition of the T cell receptor repertoire in nude mice. J. Immunol. 1987, 138:3873-3876.
28. MaImberg K.J. Effective immunotherapy against cancer: A question of overcoming immune suppression and immune escape?. Cancer Immunol. Immunother. 2004, 53:879-892.
29. Morath C., Mueller M., Goldschmidt H., Schwenger V., Opelz G., Zeier M. Malignancy in renal transplantation. J. Am. Soc. Nephrol. 2004, 15:1582-1588.
30. Myron Kauffman H., McBride M.A., Cherikh W.S., Spain P.C., Marks W.H., Roza A.M. Transplant tumor registry: Donor related malignancies. Transplantation 2002, 74:358-362.
31. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58:3491-3494.
32. Old L.J., Boyse E.A. Immunology of experimental tumors. Annu. Rev. Med. 1964, 15:167-186.
33. Pham S.M., Kormos R.L., Landreneau R.J., Kawai A., Gonzalez-Cancel I., Hardesty R.L., Hattler B.G., Griffith B.P. Solid tumors after heart transplantation: Lethality of lung cancer. Ann. Thorac. Surg. 1995, 60:1623-1626.
34. Prehn R.T., Main J.M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 1957, 18:769-778.
35. Reichert T.E., Day R., Wagner E.M., Whiteside T.L. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998, 58:5344-5347.
36. Riccobon A., Gunelli R., Ridolfi R., De Paola F., Flamini E., Fiori M., Saltutti C., Petrini M., Fiammenghi L., Stefanelli M., et al. Immunosuppression in renal cancer: Differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest. 2004, 22:871-877.
37. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
38. Russell J.H., Ley T.J. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 2002, 20:323-370.
39. Rygaard J., Povlsen C.O. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta. Pathol. Microbiol. Scand. Microbiol. Immunol. 1974, 82:99-106.
40. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102:18538-18543.
41. Schmielau J., Nalesnik M.A., Finn O.J. Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin. Cancer Res. 2001, 7(Suppl. 3):933s-939s.
42. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
43. Shinkai Y., Rathbun G., Lam K.P., Oltz E.M., Stewart V., Mendelsohn M., Charron J., Datta M., Young F., Stall A.M., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate VDJ rearrangement. Cell 1992, 68:855-867.
44. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., Kawano T., Pelikan S.B., Crowe N.Y., Godfrey D.I. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000, 191:661-668.
45. Smyth M.J., Thia K.Y., Street S.E., MacGregor D., Godfrey D.I., Trapani J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 2000, 192:755-760.
46. Smyth M.J., Crowe N.Y., Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 2001, 13:459-463.
47. Staibano S., Mascolo M., Tranfa F., Salvatore G., Mignogna C., Bufo P., Nugnes L., Bonavolonta G., De Rosa G. Tumor infiltrating lymphocytes in uveal melanoma: A link with clinical behavior?. Int. J. Immunopathol. Pharmacol. 2006, 19:171-179.
48. Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97:192-197.
49. Street S.E., Trapani J.A., MacGregor D., Smyth M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 2002, 196:129-134.
50. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974, 183:534-536.
51. Thomas L. On immunosurveillance in human cancer. Yale J. Biol. Med. 1982, 55:329-333.
52. Villegas F.R., Coca S., Villarrubia V.G., Jimenez R., Chillon M.J., Jareno J., Zuil M., Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002, 35:23-28.
53. Yasunaga M., Tabira Y., Nakano K., Iida S., Ichimaru N., Nagamoto N., Sakaguchi T. Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma. Ann. Thorac. Surg. 2000, 70:1634-1640.
54. Yoshimoto M., Sakamoto G., Ohashi Y. Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 1993, 72:2993-3001.
55. Zeier M., Hartschuh W., Wiesel M., Lehnert T., Ritz E. Malignancy after renal transplantation. Am. J. Kidney Dis. 2002, 39:E5.
56. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
57. van den Broek M.E., Kagi D., Ossendorp F., Toes R., Vamvakas S., Lutz W.K., Melief C.J., Zinkernagel R.M., Hengartner H. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 1996, 184:1781-1790.